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ABSTRACT
Objectives Australian guidelines recommend all adults 
aged 50–70 years old without existing contraindications 
consider taking low- dose aspirin (100–300 mg per day) 
for at least 2.5 years to reduce their risk of developing 
colorectal cancer. We aimed to explore clinicians’ 
practices, knowledge, opinions, and barriers and 
facilitators to the implementation of these new guidelines.
Methods Semistructured interviews were conducted with 
clinicians to whom the new guidelines may be applicable 
(Familial Cancer Clinic staff (geneticists, oncologists and 
genetic counsellors), gastroenterologists, pharmacists and 
general practitioners (GPs)). The Consolidated Framework 
for Implementation Research (CFIR) underpinned the 
development of the interview guide. Coding was inductive 
and themes were developed through consensus between 
the authors. Emerging themes were mapped onto the CFIR 
domains: characteristics of the intervention, outer setting, 
inner setting, individual characteristics and process.
Results Sixty- four interviews were completed between 
March and October 2019. Aspirin was viewed as a 
safe and cheap option for cancer prevention. GPs were 
considered by all clinicians as the most important health 
professionals for implementation of the guidelines. 
Cancer Council Australia, as a trusted organisation, was 
an important facilitator to guideline adoption. Uncertainty 
about aspirin dosage and perceived strength of the 
evidence, precise wording of the recommendation, 
previous changes to guidelines about aspirin and 
conflicting findings from trials in older populations were 
barriers to implementation.
Conclusion Widespread adoption of these new guidelines 
could be an important strategy to reduce the incidence 
of bowel cancer, but this will require more active 
implementation strategies focused on primary care and 
the wider community.
Trial registration number Australian New Zealand 
Clinical Trials Registry (ACTRN12620001003965).
INTRODUCTION
In 2019, colorectal cancer (CRC) was the 
second most commonly diagnosed cancer in 
Australia in men and women (9069 cases and 
7329 cases, respectively).1 In November 2017, 
Cancer Council Australia (CCA) updated 
their guidelines for the prevention of CRC 
to recommend that all people aged 50–70 
years who are at average risk of CRC actively 
consider taking low- dose aspirin to reduce 
their risk of CRC.2 Despite the publication 
of these national guidelines recommending 
a significant change in CRC prevention 
strategy, it has not been accompanied by an 
implementation strategy, rather relying on 
passive diffusion of the guidelines into clin-
ical practice.
The new guidelines were endorsed by 
the National Health and Medical Research 
Council and adopted by the Royal Austra-
lian College of General Practitioners. Meta- 
analyses of randomised controlled trials of 
low- dose aspirin have demonstrated reduced 
incidence and mortality from CRC by 25% 
and 33%, respectively, as well as a 33% reduc-
tion in all- cause cancer mortality, when taken 
for at least 2.5 years.3 In addition to reducing 
the risk of CRC, aspirin also reduces the risk 
of cardiovascular disease (CVD) including 
myocardial infarctions, ischaemic strokes and 
transient ischaemic attacks by 6% per annum 
in primary prevention trials.4 However, 
Strengths and limitations of this study
 ► We recruited a large and diverse group of partici-
pants representing different clinical disciplines, var-
ied length of experience and work settings.
 ► We applied an established theoretical framework to 
study guideline implementation.
 ► We recruited participants only from one state, 
Victoria, but we believe our findings are likely to be 
transferable to other Australian clinicians.
 ► We acknowledge that there may be other barriers 
and facilitators experienced by clinicians from re-
mote locations.
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aspirin can cause side effects including gastrointestinal 
haemorrhage, peptic ulcer and haemorrhagic stroke.
This project aimed to explore clinicians’ practices, 
knowledge, opinions, and barriers and facilitators to 
the implementation of these guidelines, with the inten-
tion of developing implementation methods to increase 
the uptake of aspirin for CVD and CRC prevention and 
reduce development of CRC in the Australian population.
METHODS
Approach
A qualitative case study using semistructured interviews 
was conducted with a range of health professionals whom 
the new guidelines were most likely to directly impact, 
including gastroenterologists, geneticists, oncologists, 
genetic counsellors and general practitioners (GPs). A 
constructivist paradigm was used to generate new ideas 
from participants, using interviews to explore current 
practice, knowledge and opinions toward recommending 
aspirin to people at average risk of CRC and potential 
barriers and facilitators to implementing the guidelines.
Setting and sampling strategy
Recruitment was done through personal networks of the 
authors, as well as through social media posts, emailing 
through the Familial Cancer Centre (FCC) staff email list 
in the Parkville Precinct and cold calling general prac-
tices through the University of Melbourne’s Department 
of General Practice Victorian Research and Education 
Network database. From these different sources of partic-
ipants, we purposively sampled to achieve maximum vari-
ation in profession type, age, gender, years of experience 
and those working in both rural and urban Victoria, and 
public and private practice settings. As we sent out recruit-
ment messages through different sources, all participants 
opted in on their own. All participants provided written 
consent. GPs, as private practitioners, were reimbursed 
$100 for their time as this group was the most difficult to 
recruit. Recruitment of all participants occurred between 
February and September 2019.
Data collection techniques
A semistructured interview guide was developed based 
on the Consolidated Framework for Implementation 
Research (CFIR)5 (table 1). CFIR is a conceptual frame-
work developed to guide the assessment of implementa-
tion contexts. It consists of 5 domains and 39 constructs 
representing all areas of a healthcare setting that impact 
on the successful implementation of a new interven-
tion.6 The five overarching CFIR domains cover aspects 
of the design and cost or the intervention characteristics; 
aspects of organisations and how they operate in the inner 
setting; individuals within the organisations or character-
istics of individuals like the culture and leadership, how 
outside organisations or outer settings and beliefs, and 
implementation processes impact on successful imple-
mentation of an intervention.
The interview questions were adapted from the online 
CFIR guide, which provides a list of potentially rele-
vant interview questions for each of the constructs.5 In 
this study, the ‘intervention’ was defined as the national 
guideline recommending consideration of aspirin for 
CRC prevention (online supplemental material 1).
The interviews were conducted by three researchers, 
authors SM, PA and TY, who had no existing relation-
ships with the participants. The interviewing researchers 
disclosed their position in the research to the partici-
pants and they were aware why the research was being 
conducted. Researcher SM who interviewed the GPs, 
geneticists, oncologists and genetic counsellors is a highly 
experienced female qualitative researcher. Researchers 
PA, who interviewed pharmacists, and TY, who interviewed 
gastroenterologists, both were male students who were 
trained in qualitative methods and supervised by expe-
rienced qualitative researchers (SM, JM, JE). Interviews 
were audio recorded and transcribed verbatim. Field notes 
on the time and location were recorded in researchers’ 
Table 1 Overview of the Consolidated Framework for Implementation Research (CFIR); the CFIR provides constructs that 
have been associated with effective implementation6
Characteristics of 
intervention Inner setting Outer setting Individuals involved
Implementation 
process
 ► Intervention source
 ► Evidence strength and 
quality




 ► Design quality
 ► Cost
 ► Structural 
characteristics
 ► Networks and 
communications
 ► Culture
 ► Implementation 
climate
 ► Patient needs and 
resources
 ► Cosmopolitanism
 ► Peer pressure
 ► External policies 
and incentives
 ► Knowledge and 
beliefs about the 
intervention
 ► Self- efficacy
 ► Individual stage of 
change
 ► Individual 
identification with 
organisation





 ► Reflecting and 
evaluating
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notebook following the interviews. Researchers met regu-
larly to review the interview transcripts and discuss data 
and the emerging themes. Interview transcripts were not 
returned to participants.
Analysis
Qualitative transcript data were managed using NVivo 
V.12.7 The interviews for each type of participant, FCC 
staff, GPs, gastroenterologists and pharmacists, were 
initially analysed separately. Complete coding of each 
interview was conducted by the author who interviewed 
the participant where everything that was spoken by the 
participants was organised into specific topics. At the first 
level of coding, codes were produced inductively for each 
of the participant professional groups on completion. For 
enhanced interpretive rigour, several interviews in each 
participant group were co- coded by another researcher 
and progressively checked in regular researcher meet-
ings. The coding for several interviews per participant 
type was checked by a second researcher.
After first- level coding, codes were grouped into themes. 
Thematic analysis was employed at this level where themes 
emerged from the first- level coding through discussions 
between the researchers. About 20 themes per profes-
sional group type were defined. Themes from each profes-
sional group type were discussed between the researchers 
and brought together if they could be. Themes were then 
mapped onto the domain and constructs from the CFIR6 : 
characteristics of intervention, outer setting, inner setting, 
characteristics of individuals and process (table 1).
Patient and public involvement
No patient involvement.
RESULTS
Sixty- four participants were interviewed (table 2). Inter-
views ranged from 20 to 50 min and were face- to- face 
in the participants’ place of work (clinic, pharmacy or 
hospital consulting or meeting room), except for four 
GPs who were interviewed over the phone. The researcher 
and participants were the only ones present during the 
interviews, except for with pharmacists if there were shop-
keepers or pharmacy assistants present. The results are 
presented according to the domains of CFIR (table 3).
Characteristics of the intervention
Aspirin
Many participants expressed confusion regarding the 
dose of aspirin recommended for CRC prevention. While 
some participants were comfortable deciding on a dose 
within the 100–300 mg range specified in the guidelines, 
others felt that this dose range indicated uncertainty in 
the guidelines (quotations 1a and 1b).
1a Well I think the range is ambiguous there. The 
numbers are not ambiguous at all there I suppose but 
it’s just - it’s out with normal practice I guess. (GP, 30 
years old)
1b And I think the risk in data coming out is how much is 
useful, like the dosage. We used to think that a low dose 
used to be good for other cardiovascular events, but in 
fact maybe it isn't depending on gender, age and weight. 
(Gastroenterologist, 47 years old)
Aspirin was perceived as cheap, safe and readily avail-
able by many participants, who stated this would facilitate 
their prescribing and patient uptake. With the rising costs 
of healthcare, participants thought the cheap nature of 
aspirin facilitated the implementation of the guidelines 
(quotation 1c). Barriers to implementation included 
concerns about possible side effects of aspirin such as 
gastrointestinal bleeding and contraindications in people 
with multiple comorbidities (quotation 1d).
1c It’s cheap, which is the other thing; and, again, in the 
Australian healthcare system, where there are costs asso-
ciated with a lot of treatments, to be able to recommend 
something that is - we’re saying safe, the exception being 
the gastric irritation, and effective, and it’s not going to 
break the bank for them to use it. (GP, 62 years old)
Table 2 Characteristics of participants (N=64)
Characteristics
Mean age (years) 41
Sex, female (n) 35
Profession (n)
  Gastroenterologist 17
  Pharmacist 14
  General practitioner 16
  Familial cancer centre (FCC) staff
   Genetic counsellor 10
   Geneticists 4
   Oncologist 3
Years in profession (n)
  <10 23
  10–19 22
  20–29 8
  30+ 11
Work setting
  General practice (%)
   Bulk- billing clinic 31
   Private 69
  Hospital (gastroenterologists and FCC staff) (%)
   Public 77
   Private 23
  Pharmacy (%)
   Hospital 36
   Community 64
FCC, Familial Cancer Centre.
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1d And in terms of weighing up the side effects 
from aspirin, we’ve got the issue of the potential for 
those individuals who have got other comorbidities 
whether it’s renal or allergies to aspirin or risk of 
stroke etc etc. You’ve got to weigh all those factors 
up before you consider putting someone on aspirin. 
(Gastroenterologist, 59 years old)
CCA guideline
Many participants mentioned the specific phrasing of the 
guidelines, namely that aspirin should be ‘actively consid-
ered’. This language did not sufficiently encourage them 
to prioritise the recommendation, and implied uncer-
tainty about the strength of evidence (quotation 1e).
1e Because it’s not strong, also, perhaps that’s some-
thing that will be its - not its downfall, but will be 
negative because we already have a lot of strong 
guidelines. (Geneticist, 32 years old)
Inner setting
Despite the variety of specialties and workplace types, 
a common theme emerged of competing demands on 
clinicians’ time- limiting capacity to discuss aspirin for the 
prevention of CRC (quotations 2a and 2b). Pharmacists 
suggested they could support GPs in counselling patients, 
given GPs have relatively short consultation times with their 
patients. Pharmacists commented on the closeness of their 
location to GP clinics and their potential to reiterate advice 
about aspirin given by the GP (quotation 2c).
2a I think time’s our major challenge. There’s just 
not enough time to… especially that the pace that 
endoscopy list goes is fast and I think in private it’s 
much faster. Public, even then; even if it’s not pace, 
the patients had an anaesthetic - it’s not really an 
appropriate time to be talking to them about long- 
term stuff. (Gastroenterologist, 50 years old)
2b So we only actually see people when we can of-
fer genetic testing and the rest of our work is done 
over the phone or we send letters. We are absolutely 
flat out at the moment. This is probably the only 
time today I will be sitting and not running around. 
(Genetic counsellor, 35 years old)
2c I think, we should, way of promoting it, and prob-
ably we should be more proactive with it, GPs tend 
to not… especially, one of the pharmacies I work at 
is next to a bulk billing clinic doctors are very much 
get them in, get them out, and don’t spend much 
time with them. so that’s where we can often come 
in to be that extra person that can either reinforce 
what the doctor’s told them or suggest other things. 
So, we should be there in the front line, yeah, pro-
moting health. (Pharmacist, 50 years old)
Outer setting
CCA was perceived as a trustworthy organisation and this 
gave greater weight to and trust in the guidelines (quota-
tion 3a).
3a Look as long as this is done by the Cancer Council 
of Victoria, I'm trusting them so it depends who is it 
behind, but this is a credible source of information I 
would have hoped. (GP, 58 years old)
Table 3 Results of themes from interviews with general practitioners (GPs), gastroenterologists, Familial Cancer Clinic staff 
(FCC staff) and pharmacists mapped onto the Consolidated Framework for Implementation Research
Characteristics of 
intervention Inner setting Outer setting Individuals involved
Implementation 
process
 ► The participants 
expressed confusion 
around the aspirin 
dosing (100–300 mg)
 ► Some facilitators to 
aspirin implementation 
included the low cost, 
availability and safety
 ► The ‘actively 
considered’ wording of 
the guidelines implied 
some uncertainty about 
the strength of the 
evidence
 ► The aspirin guidelines 
have changed over 
time which presents 
as a barrier to 
implementation




be a barrier to 
implementation 
as they are 
usually very 
busy
 ► Pharmacists 
specifically saw 
their role to 
support what 
the GPs advise, 
and thought 
they should 
reiterate this to 
patients
 ► As the guidelines 
were first published 
by the Cancer 
Council Australia, 
they were more 
trustworthy
 ► The ASPREE trial 
although it was a 
study done in the 
elderly (70–80 years 
old) population, it 
introduced some 
hesitancy even for 
the population aged 
50–70 years old
 ► The guidelines have 
changed a lot over 
time for CVD
 ► Geneticists, pharmacists 
and gastroenterologists 
saw their role as 
advocates of the 
guidelines
 ► All clinicians agreed 
that it is GPs’ role to 
implement the guidelines 
into general practice, 
GPs agreed it was their 
role
 ► FCC staff were aware of 
the guidelines, but other 
clinicians had limited 
knowledge
 ► Participants thought 
of themselves as 
early adopters 
but agreed that 
it takes time for 
most clinicians to 
implement new 
interventions
 ► Participants agreed 
that patients would 
be receptive to the 
recommendations
 ► A decision aid 
would be helpful 
in facilitating a 
discussion with 
patients
ASPREE, Aspirin in Reducing Events in the Elderly; CVD, cardiovascular disease.
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The initial results of the Aspirin in Reducing Events 
in the Elderly (ASPREE) trial were published after the 
CCA national clinical guidelines were released, and 
shortly before interviews for this study were conducted.8 
The ASPREE trial showed low- dose aspirin provided no 
benefit in participants aged 70–80 years over a short- term 
follow- up of 4.7 years.9 Some participants in our study, 
despite varying degrees of knowledge of the ASPREE trial 
results, were hesitant to recommend aspirin for people 
even in the group age 50–70 years covered by the guide-
lines, due to the findings of the ASPREE trial despite 
being conducted in a different age cohort (quotations 3b 
and 3c).
3b So that negative study for aspirin in older pa-
tients; kind of makes me think- should I be giving it 
to someone with average risk of colorectal cancer? 
(Gastroenterologist, 32 years old)
3c So there was a big study here in Australia, and then 
a little bit of input from the US done over the last few 
years, came out last year, the ASPREE study, so I did 
a talk on it, so I looked at the primary prevention of 
aspirin in the cardiovascular disease, and it showed 
that low- dose aspirin for healthy older adults had no 
impact on primary prevention and cardiovascular 
risk. (Pharmacist, 26 years old)
Guidelines on the use of aspirin for disease prevention 
have changed over time, generating confusion among 
participants. Historically, aspirin was recommended for 
primary prevention of CVD in certain at- risk patients, 
but guidelines were later altered, recommending it only 
for secondary prevention.10 11 Participants stated that it 
is hard to keep up with the latest recommendations, and 
that this ongoing change in advice caused reluctance to 
recommend them (quotation 3d).
3d With aspirin, it was always for stroke prevention, 
and now they’re turning around and saying no, we 
shouldn’t be doing it for that! And you sort of won-
der, well, is this going to be the same sort of thing? 
The, one of the issues with medications and guide-
lines as such is that they keep changing. (Pharmacist, 
50 years old)
Characteristics of individuals
Whose role is it to recommend aspirin?
Hospital- based clinicians generally supported the guide-
lines and saw their role as advocates rather than imple-
menters of the guidelines (quotations 4a and 4b). All 
participants, including GPs, saw that the primary respon-
sibility to implement the aspirin guidelines rested in 
primary care (quotations 4c and 4d).
4a So, you know I’m a Geneticist. I think talking to 
GPs and Gastroenterologists would be a much better 
group [laughs] than Geneticists. (Geneticist, 34 years 
old)
4b People are still very GP centred, so a lot of, even if 
we suggest things like this, a lot of people would still 
then go and talk to their GP before they decided to 
start something. (Pharmacist, 50 years old)
4c If you understand what I mean, it’s absolutely…I 
agree with those specialists, I do think it is part of the 
role of the GP to talk about these preventative health 
issues specifically prescribing aspirin. (GP, 28 years 
old)
4d It’s interesting when new guidelines come out, be-
cause guidelines come out all the time, and this is a 
really - this is our bread and butter as a GP. (GP, 48 
years old)
Knowledge/awareness of the CCA guidelines
Knowledge and awareness of the guidelines were mixed. 
The FCC staff were more knowledgeable of the guidelines, 
specifically as they work with populations at increased 
risk of CRC, and awareness of recommendations about 
aspirin use in people with Lynch syndrome. Whereas GPs, 
pharmacists and gastroenterologists were either unaware 
or had limited knowledge of the guidelines (quotations 
4e and 4f).
4e All I know about low- dose aspirin in bowel cancer 
is that it can be used, but in certain populations, but 
beyond that, I actually really don't know. (Geneticist, 
32 years old)
4f I would say that going across, we have three dif-
ferent clinicians at work, and I don't think I've ever 
heard them recommend aspirin for someone who ac-
tually doesn’t have something like Lynch syndrome. 
(Genetic counsellor, 57 years old)
Process
Implementation of the CCA guidelines
While most participants considered themselves as early 
adopters, they admitted that clinicians in general would 
wait before adopting new clinical guidelines (quotation 
5a). Most health professionals agreed that patients would 
be receptive to taking extra medication such as aspirin 
for CRC prevention (quotation 5b). Nevertheless, a deci-
sion aid was thought to be potentially useful to facilitate 
discussion about the risks and benefits of taking aspirin 
(quotation 5c). Several participants could see how they 
could discuss aspirin as part of their usual consultation 
(quotation 5d).
5a Other doctors like to be on the tail end because 
they've been burnt a few times when things have kind 
of flipped back the other way. (GP, 38 years old)
5b You know, I think the people who already take tab-
lets for something find it quite easy to beguile an extra 
tablet. So, someone’s already on a cholesterol tablet, 
they're on a high blood pressure tablet, it’s easy for 
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them to add aspirin to that. (Gastroenterologist, 60 
years old)
5c Well that (a decision aid) might have been useful 
for the patient to show them what could happen and 
how effective it is if they ask. (GP, 58 years old)
5d You know, I appreciate they’re guidelines and 
they’re not mandatory, and if it fits in with the way I 
would practice, I’m happy to sort of incorporate them 
into what I do. (Gastroenterologist, 65 years old)
DISCUSSION
This is the first study to our knowledge to examine the 
perspectives of a wide range of Australian clinicians 
about recommending aspirin to reduce bowel cancer 
risk. Aspirin was considered as readily available, afford-
able and safe. However, the ambiguity about the recom-
mended dose and perceived strength of the evidence 
was a concern for several clinicians. The media attention 
about the ASPREE trial12 added to the perceived uncer-
tainty about the evidence. Busy work environments meant 
limited time to spend on prevention. The endorsement 
from CCA, a nationwide not- for- profit organisation, 
meant the guidelines were perceived as trustworthy and 
therefore more likely to be implemented.
FCC staff and gastroenterologists are generally aware of 
aspirin recommendations for patients at increased CRC 
risk and suggested that GPs are better placed to discuss 
aspirin in those at average risk. These hospital specialists 
felt they could advocate the use of aspirin but the ulti-
mate responsibility for initiation rested in general prac-
tice. Pharmacists similarly felt they could facilitate the 
process but would not initiate discussions about aspirin. 
GPs agreed that this was part of their role, for example 
when discussing bowel cancer screening, but had limited 
awareness of the guidelines.
There is often a large investment of time, resources 
and clinical expertise involved in producing national 
clinical guidelines, however, there is typically no accom-
panying strategy to implement them.13 14 Between 2003 
and 2007, 313 clinical practice guidelines were produced 
in Australia by over 80 guideline producers,15 but with 
limited clinical uptake.16 17
The uptake of guidelines into clinical practice is influ-
enced by several factors including the guideline charac-
teristics, ease of implementation, clarity of the guidelines 
and individual clinicians’ familiarity with the interven-
tion and evidence.18 Our study highlights several of these 
factors which could act as barriers to widespread imple-
mentation of the aspirin guidelines. Superficially, one 
might expect recommending a familiar, low- cost, over- 
the- counter drug would be easily implemented. But lack 
of clarity, partly due to the specific wording of the recom-
mendation, could alter perceptions of the evidence and 
jeopardise uptake of the guideline.
Uncertainties among clinicians about the evidence for 
aspirin in disease prevention is exacerbated by changes in 
recommendations about its use in CVD. The CCA guide-
line specifically considered the evidence as it relates to 
preventing CRC. It did not discuss related evidence of 
reduced incidence and mortality from other cancers3 or 
for the primary prevention of CVD.4 The US Preventative 
Services Taskforce recommends aspirin for CRC preven-
tion only in people who are also at moderately increased 
risk of CVD.19 In addition, their recommendations 
about its use are stronger for people aged 50–59 years, 
compared with those aged 60–69 years because the risk of 
serious side effects from aspirin increases with age.
There was little awareness among many participants of 
the additional effects of aspirin on all- cancer incidence 
and mortality, but this is an important additional consider-
ation for patients when making informed decisions about 
taking aspirin. Clinicians in our study recognised the 
potential benefit of a decision aid to support discussions 
about taking aspirin. There is strong evidence to show 
that decision aids can support informed decision- making, 
particularly when decisions require weighing up benefits 
and risks which are preference sensitive.20 Patients need 
to understand the potential benefits of aspirin in terms 
of reduced incidence and death from cancer and CVD, 
and harms from gastrointestinal and intracranial haem-
orrhage. In a vignette study testing graphical approaches 
to communicating these harms and benefits from aspirin, 
over 70% of Australian patients aged 50–70 years were 
willing to take aspirin for disease prevention.21 The use 
of a decision aid has the potential to inform the clinicians 
which addresses a major barrier to implementation, as 
GPs have limited awareness of the guidelines. A decision 
aid would enhance the clarity of the recommendation 
and facilitate a discussion about the aspirin guidelines 
with patients.
Implications and limitations
In this in- depth qualitative study, we recruited a large 
sample of diverse participants representing different 
clinical disciplines, varied length of experience and work 
settings. Although we recruited participants only from 
Victoria, we believe our findings are likely to be transfer-
able to other Australian clinicians although we acknowl-
edge that there may be other barriers and facilitators 
experienced by clinicians from remote locations.
The national guidelines on aspirin represent an 
important new approach to reducing the incidence and 
mortality of bowel cancer in Australia. But the absence of 
a strategic and more active implementation plan means 
these guidelines are less likely to be translated into clin-
ical practice.22 Specific implementation strategies for 
general practice are necessary to increase the awareness 
and uptake of these guidelines. Our findings suggest 
that a stronger statement of recommendation and clarity 
about dosage are required. Engagement with pharmacists 
is also necessary to ensure they are aware of the guidelines 
and are prepared to endorse any advice from someone’s 
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GP about using aspirin. These implementation strategies 
could be supplemented by approaches to raise awareness 
in the community about the role of aspirin and decision 
aids to facilitate discussions between GPs and patients 
and support informed choices about CRC prevention.
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